In 'Conservative' Estimate, Investment Firm Predicts PacBio Will Ship 46 Instruments in 2011

William Blair initiated coverage of PacBio this week, but predicted slightly lower instrument sales than consensus estimates due to "uncertainty about the adoption trajectory beyond early users."

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.